Clinical Trial Update: Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring safety and efficacy of a three-drug combination (fruquintinib, chidamide, and sintilimab) in third- and later-line MSS/pMMR met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Chidamide (chidamide)
• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Dai, Guanghai | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: RECRUITING